Emricasan

• GMP format available

Emricasan is a potent, selective, and orally bioavailable pan-caspase inhibitor. It is designed to inhibit the activity of caspases, which are enzymes involved in the process of apoptosis (programmed cell death) and inflammation.

Emricasan has been investigated for its potential therapeutic applications in several conditions, including:

• Liver Diseases: Chronic liver diseases such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis.
• Cardiovascular Diseases: Conditions involving cardiac apoptosis and inflammation.
• Neurodegenerative Diseases: Diseases characterized by excessive neuronal apoptosis, such as Alzheimer’s disease and Huntington’s disease.